Alto Neuroscience, Inc. (NYSE:ANRO) Financings
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock Announced: about US$100M · US$26.48 a share · BofA Securities +4 Dealers: BofA Securities (co-lead), Stifel (co-lead), William Blair (co-lead), Baird (co-lead), Jones Buyers: EcoR1 Capital Use of proceeds: Accelerate and expand clinical development of ALTO-207, including an additional Phase 3 trial in treatment-resistant depression, and working capital | Jul 13, 2026 |
| Private placement of private placement financing (PIPE) Closed: US$50M raised · US$5.914 a share Buyers: Perceptive Advisors (Led the financing); Commodore Capital; Vestal Point Capital; Vivo Capital Use of proceeds: To support the accelerated development of ALTO-207 following the successful FDA meeting | Nov 12, 2025 |